CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
enzastaurin hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00407758
NCT00407758Phase 2Completed
CompareCT.gov

A Phase II Evaluation of Enzastaurin (Lilly IND # 60, 933) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Gynecologic Oncology Group·interventional·Posted Dec 5, 2006·Updated Mar 20, 2019

In Brief

A Phase 2 clinical trial evaluating enzastaurin hydrochloride for Ovarian Cancer and Primary Peritoneal Cavity Cancer. Completed, enrolled 28 participants across 16 sites.

Detailed Summary

RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well enzastaurin works in treating patients with persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Primary Peritoneal Cavity Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 5, 2006
Enrollment StartNov 1, 2006
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.8 yearsPosted 19.6 years ago

Interventions

enzastaurin hydrochloridedrug